Antiretroviral Guidelines

US DHHS Guidelines with Australian commentary

Characteristics of CD4 Post-Attachment Inhibitor

Last Updated: October 25, 2018; Last Reviewed: October 25, 2018

Generic Name
Trade Name
Formulation Dosing Recommendations Serum Half-Life Elimination/ Metabolic Pathway Adverse Events
  • Single-dose 2 mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab
  • Administer a single loading dose of IBA 2000 mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800 mg IV infusion over 15 minutes every 2 weeks.
  • See prescribing information for additional instruction in preparation, storage, administration, and monitoring.
~64 hours Not well defined.
  • Diarrhea
  • Dizziness
  • Nausea
  • Rash
Key to Acronyms: IBA = ibalizumab; IV = intravenous